M&A Deal Summary |
|
|---|---|
| Date | 2017-03-17 |
| Target | Threshold Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Molecular Templates |
| Sellers(s) |
Alta Partners
Three Arch Partners |
| Deal Type | Merger |
| Advisor(s) | Ladenburg Thalmann & Co. (Financial) Cooley (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Sector | Life Science |
| Revenue | 53M USD (2023) |
Molecular Templates is focused on the discovery, development, and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases. Molecular Templates is based in Austin, Texas.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Merger M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2017 M&A | 1 of 1 |
| Category | Venture Capital Firm |
|---|---|
| Founded | 1996 |
| PE ASSETS | 2.6B USD |
| Size | Large |
| Type | Sector Focused |
Alta Partners is a venture capital firm that targets investments in early and later stage life science companies, including biopharmaceuticals, medical technology, and information technology businesses. Alta was formed as an early stage investor but has since expanded its investment range to provide later stage growth capital to private and young public companies. Alta was established in 1996 and is headquartered in San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 79 of 85 |
| Sector: Life Science M&A | 61 of 65 |
| Type: Merger M&A Deals | 1 of 2 |
| State: California M&A | 37 of 41 |
| Country: United States M&A | 69 of 75 |
| Year: 2017 M&A | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-11-05 |
ZS Pharma
Coppell, Texas, United States ZS Pharma, founded in 2008, is a privately held specialty pharmaceutical company based in Coppell, Texas and Menlo Park, CA. Our core focus is the research and development of highly selective ion-trap therapies to treat serious medical conditions. |
Sell | $2.7B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-07-31 |
DiscoveRx
Fremont, California, United States DiscoveRx Corp. is an innovative company that develops, manufactures, and commercializes reagents, complete cell-based assay kits, profiling and screening services as well as other disruptive solutions for the drug discovery, screening, and life science markets. EFC technology is a proven, established screening platform in most major pharmaceutical companies. With over 900 stable cell lines, 4500 drug discovery assays and kits, and both custom and off-the shelf services, DiscoverX is one of the most trusted and utilized drug discovery portfolios in the world. |
Sell | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 1993 |
| PE ASSETS | 1.0B USD |
| Size | Large |
| Type | Sector Agnostic |
Three Arch Partners is an investor in healthcare companies, including medical devices, diagnostics, and healthcare services. Three Arch primarily invests in early stage companies, however the Firm will consider select later stage investments. Three Arch typically invests alongside others and looks to commit $100k to $15 million per investment. Three Arch Partners was formed in 1993 and is based in San Mateo, California.
| DEAL STATS | # |
|---|---|
| Overall | 24 of 24 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Merger M&A Deals | 1 of 1 |
| State: California M&A | 17 of 17 |
| Country: United States M&A | 24 of 24 |
| Year: 2017 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-01-11 |
Inova Labs
Austin, Texas, United States Inova Labs, Inc. is a medical device company specializing in the development and commercialization of innovative oxygen therapy products. |
Sell | - |
